PT  - JOURNAL ARTICLE
AU  - Chirwa, Emmanuel
AU  - Mulundu, Georgina
AU  - Ndashe, Kunda
AU  - Kanongesha, Kalo
AU  - Kachinda, Wezi
AU  - Simpokolwe, Kaziwe
AU  - Hang’ombe, Bernard Mudenda
TI  - Antimicrobial Susceptibility Pattern and Detection of Extended-Spectrum Beta-Lactamase (blaCTX-M) Gene in <em>Escherichia coli</em> from Urinary Tract Infections at the University Teaching Hospital in Lusaka, Zambia
AID  - 10.1101/2020.05.16.20103705
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.16.20103705
4099  - http://medrxiv.org/content/early/2020/05/18/2020.05.16.20103705.short
4100  - http://medrxiv.org/content/early/2020/05/18/2020.05.16.20103705.full
AB  - Background Urinary tract infections caused by Extended Spectrum Beta-Lactamase producing Escherichia coli are increasing globally and yet treatment still remains a challenge due to antibiotic resistance of the causative agent.Objectives The aim of the study was to determine the antimicrobial susceptibility pattern and detect the presence of blaCTX-M gene in Escherichia coli isolated from urinary tract infection patients at the University Teaching Hospital, Lusaka, Zambia.Methodology This was a cross sectional study that involved collection of urine samples from patients who were diagnosed with urinary tract infections. The samples were cultured on MacConkey agar complemented with cefotaxime and Polymerase Chain Reaction was performed to confirm the Extended Spectrum Beta-Lactamase producers by detecting the CTX-M gene. Antimicrobial susceptibility tests were conducted using standard methods.Results A total of 327 urine samples were cultured and 15 (4.6%) of these samples were positive ESBL producers. The isolates showed complete resistance to ampicillin and cotrimoxazole.Conclusion Multi drug resistant Extended Spectrum Beta-Lactamase producing Escherichia coli was detected in 4.6 % of UTI patients at the University Teaching Hospital.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the staff development office of Lusaka Apex Medical University.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data obtained in the study is available to readers and reviewer is available within the manuscript